Palivizumab immunoprophylaxis: Use in clinical practice, safety and beneficial effects in France;Modalités d'utilisation, tolérance et bénéfice du palivizumab dans la prévention des infections à VRS en France : saison 2005-2006

Archives de Pediatrie

Volumn 16, Issue 11, 2009, Pages 1443-1452

  Pinquier, D ^a   Gouyon, J B ^b   Fauroux, B ^c   Mons, F ^a   Vicaut, E ^d   Bendjenana, H ^e   Rouffiac, E ^e   Marret, S ^a   Aujard, Y ^f  

^a EA 4309   (France)

^b HÔPITAL DU BOCAGE   (France)

^c ARMAND TROUSSEAU HOSPITAL   (France)

^d HÔPITAL FERNAND WIDAL   (France)

^e Abbott   (France)

^f HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB;

AGE; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; FRANCE; GESTATIONAL AGE; HEALTH CARE FACILITY; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; IMMUNOPROPHYLAXIS; INFANT; MAJOR CLINICAL STUDY; MALE; PREMATURITY; PRESCRIPTION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; BRONCHOPULMONARY DYSPLASIA; DISEASE OUTBREAKS; FEMALE; FOLLOW-UP STUDIES; FRANCE; GESTATIONAL AGE; HEART DEFECTS, CONGENITAL; HOSPITALIZATION; HUMANS; INFANT; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; INFANT, PREMATURE, DISEASES; MALE; MULTICENTER STUDIES AS TOPIC; PROSPECTIVE STUDIES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 70350338855     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcped.2009.08.008     Document Type: Article

References (19)

1. Aujard Y., and Fauroux B. Risk factors for severe respiratory syncytial virus infection in infants. Respir Med 96 Suppl. B (2002) 9-14
2. The IMpact-RSV study group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102 (1998) 531-537
3. Sorrentino M., and Powers T. Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The palivizumab outcomes study group. Pediatr Infect Dis J 19 (2000) 1068-1071
4. Lacaze-Masmonteil T., Rozé J.C., Fauroux B., et al. Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with palivizumab as RSV prophylaxis. Pediatr Pulmonol 34 (2002) 181-188
5. Oh P.I., Lanctjt K.L., Yoon A., et al. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes. Pediatr Infect Dis J 21 (2002) 512-518
6. Pedraz C., Carbonell-Estrany X., Figueras-Aloy J., et al. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr Infect Dis J 22 (2003) 823-827
7. Grimaldi M., Gouyon B., Michaut F., et al. Severe respiratory syncytial virus bronchiolitis: epidemiologic variations associated with the initiation of palivizumab in severely premature infants with bronchopulmonary dysplasia. Pediatr Infect Dis J 23 (2004) 1081-1085
8. Feltes T.F., Cabalka A.K., Meissner H.C., et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 143 (2003) 532-540
9. ®) chez les enfants atteints de cardiopathie congénitale. Arch Pediatr 11 (2004) 1402-1405
10. Romero J.R. Palivizumab prophylaxis of respiratory syncitial virus disease from 1998-2002: results from four years of palivizumab usage. Pediatr Infect Dis J 22 (2003) S46-S54
11. Simoes E.A. Immunoprophylaxis of respiratory syncytial virus: global experience. Respir Res 3 Suppl. 1 (2002) 26-33
12. Subcommittee on diagnosis and management of bronchiolitis. Diagnosis and management of bronchiolitis. Pediatrics 2006;118:1774-93.
13. Dupont L., Marret S., Brossard V., et al. À propos du risque de réhospitalisation du nouveau-né de faible poids de naissance. Arch Pediatr 4 (1997) 287
14. Chevret L., Mbieleu B., Essouri S., et al. Bronchiolites en unité de réanimation pédiatrique : facteurs pronostiques et devenir respiratoire des nourrissons ventilés. Arch Pediatr 12 (2005) 385-390
15. Grimaldi M., Gouyon B., Sagot P., et al. Palivizumab efficacy in preterm infants with gestational age less or equal to 30 weeks without BDP. Pediatr Pulmonol 42 (2007) 189-192
16. Lacaze-Masmonteil T., Truffert P., Pinquier D., et al. Réadmission for lower respiratory tract illness in RSV prophylaxed and not prophylaxed very premature infants; incidence and risk factors. Arch Dis Child 89 (2004) 562-567
17. Anaes. Conférence de consensus sur la prise en charge de la bronchiolite du nourrisson. 21 septembre 2000.
18. Pinquier D., Gagneur A., Gras-Le Guen C., et al. Vaccine prevention in perinatal health care: parents, children and professionals. Gynecol Obstet Fertil 36 (2008) 461-468
19. Calendrier vaccinal 2008 - Avis du HCSP. BEH 2008;16-17:129-48.